Labcorp Launches ColoSense: First FDA-Approved At-Home Colorectal Cancer Screening Test

- Labcorp has launched ColoSense®, the first FDA-approved at-home colorectal cancer screening test utilizing RNA technology.
- The test aims to improve screening rates, addressing discomfort and messiness associated with traditional at-home tests.
- ColoSense is covered for eligible Medicare patients, facilitating early detection and preventive care for colorectal cancer.
Labcorp (LH) has announced the nationwide availability of ColoSense®, a groundbreaking at-home colorectal cancer screening test that utilizes RNA technology. As the first of its kind approved by the FDA, this innovative test aims to tackle the concerning statistic that nearly 40% of eligible adults are not adhering to suggested colorectal cancer screenings.
ColoSense®: A User-Friendly Screening Alternative
Research conducted by Labcorp highlights that many individuals are deterred from participating in at-home tests due to discomfort and the mess associated with sample preparation. Dr. Brian Caveney, Labcorp's chief medical officer, reinforces the company's commitment to increasing screening rates by introducing more user-friendly options. ColoSense is specifically designed to alleviate these concerns, streamlining the sample collection process to enhance patient experience.
This test has been recognized by the FDA with Breakthrough Device Designation, underscoring its potential to significantly enhance diagnostic effectiveness for serious health conditions. With a 93% sensitivity rate for average-risk individuals and an impressive 100% sensitivity for stage I colorectal cancer, ColoSense aims to detect the disease at its most treatable stage, thereby improving early intervention outcomes.
Inclusive Coverage for Essential Preventive Care
Targeting adults aged 45 to 85, ColoSense excludes individuals with specific high-risk conditions or a prior history of colorectal cancer. Following recent updates from the Centers for Medicare & Medicaid Services, this test will also be covered for eligible Medicare and Medicare Advantage patients. This coverage positions ColoSense as a critical tool in the fight against colorectal cancer, facilitating early detection and preventive healthcare.
Conclusion
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

